Adoptive immunotherapy for cancer |
| |
Authors: | Marco Ruella Michael Kalos |
| |
Affiliation: | 1. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA;2. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA Correspondence to: Michael Kalos Lilly Research Laboratories Eli Lilly and Company 450 East, 29th Street New York, NY 10016, USA Tel.: +1 646-638-5095 e-mail: kalos_michael_d@lilly.com |
| |
Abstract: | Recent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T-lymphocyte-based adoptive cell therapy to treat a broad range of malignancies. In this review, we summarize concepts, successes, and challenges for the broader development of this promising field, focusing principally on lessons gleaned from immunological principles and clinical thought. We present ACT in the context of integrating T-cell and tumor biology and the broader systemic immune response. |
| |
Keywords: | adoptive cell therapy immunotherapy chimeric antigen receptor cancer immune modulation tumor microenvironment |
|
|